June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
IASLC Highlights FDA Approval of VENTANA MET (SP44) RxDx Assay for NSCLC
Jun 29, 2025, 13:27

IASLC Highlights FDA Approval of VENTANA MET (SP44) RxDx Assay for NSCLC

International Association for the Study of Lung Cancer shared a post on LinkedIn:

“VENTANA MET (SP44) RxDx Assay receives FDA approval as a companion diagnostic for telisotuzumab vedotin-tllv in patients with high c-MET overexpression in NSCLC.

Read more in ILCN.”

Read OncoDaily’s Special Article on NSCLC․

NSCLC Lung cancer